Drugs / VRC07
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04357821 | Aug 2020 → Jun 2026 overdue | HIV infectious disease | University of California, San Francisco | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-02-14 | Gilead Sciences | Results Gilead Demonstrates Transformative Potential Impact Of Antiviral Innovation at CROI 2023 gilead.com ↗
Remdesivir Reduces Mortality in Hospitalized COVID-19 Patients Across Variant Eras |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-02-14 | Gilead Sciences | Gilead Demonstrates Transformative Potential Impact Of Antiviral Innovation at CROI 2023 gilead.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VRC07 | “ATI with single dose of VRC07 and 10-1074 at Week 34” NCT04357821 ↗ |